STOCK TITAN

4D Molecular Therapeutics Inc - FDMT STOCK NEWS

Welcome to our dedicated news page for 4D Molecular Therapeutics (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 4D Molecular Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 4D Molecular Therapeutics's position in the market.

Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announces positive interim safety and efficacy data on 4D-310 for Fabry disease cardiomyopathy, showcasing improvements in cardiac function, exercise capacity, and quality of life. The therapy demonstrated efficient delivery, transgene expression, and clearance of Gb3 substrate in cardiomyocytes, with no new adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
clinical trial
-
Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) announced the pricing of an upsized underwritten public offering of its common stock, with a 30-day option to purchase additional shares. The gross proceeds from the offering are expected to be approximately $300 million. The offering is expected to close on February 9, 2024, and is managed by Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays. The registration statement was automatically effective upon filing on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.97%
Tags
offering
-
Rhea-AI Summary
4D Molecular Therapeutics, Inc. (FDMT) has announced a public offering of $250.0 million of its common stock with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions, and the company has filed a registration statement with the SEC. The joint book-running managers for the offering are Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Barclays.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
offering
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients with severe disease activity and a high treatment burden. The study showed that 4D-150 was well tolerated, resulting in an 89% reduction in the annualized anti-VEGF injection rate. The positive interim results enable rapid advancement towards pivotal development, with Phase 3 clinical trial initiation expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
4D Molecular Therapeutics (FDMT) announces a live webcast to discuss interim data from the intravitreal 4D-150 Phase 2 PRISM clinical trial in wet AMD patients with severe disease activity and high treatment burden. The company will also provide a program update on Monday, February 5, 2024. The webcast will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial. The presentation of the interim results will also be available at the Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
conferences clinical trial
-
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that the U.S. FDA granted Rare Pediatric Disease Designation for aerosolized 4D-710, a treatment for cystic fibrosis lung disease. Promising clinical trial results showed significant CFTR expression levels and improved quality of life for patients. The company is also planning an interim data update and pivotal trial planning update for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
management
-
Rhea-AI Summary
TurnCare, a leading medical technology and services company dedicated to advancing how hospitals manage high acuity patients, proudly announces the addition of John F. Milligan, Ph.D., investor, innovator, and former CEO of Gilead, to its Board of Directors. Dr. Milligan's expertise includes driving major acquisitions to create unique industry solutions and scaling Gilead to over $21 Billion in worldwide sales with a market cap of $85 Billion. He brings a unique and valuable perspective that will help TurnCare maximize the impact of its novel patient management technologies as it scales to more networks, hospitals, and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.06%
Tags
management
-
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced clinical pipeline progress, partnership with Arbor Biotechnologies, and organizational updates. The company ended 2023 with $300 million in estimated cash, expecting to fund operations into H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) have announced a strategic partnership to co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system (CNS) diseases with high unmet medical needs. The initial product candidate will target amyotrophic lateral sclerosis (ALS), with additional targets expected to be in diseases with high unmet needs in both rare and large patient populations. The costs and profits will be shared evenly between the two companies, and Arbor will lead the research, development, and commercialization efforts on the first product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
partnership
4D Molecular Therapeutics Inc

Nasdaq:FDMT

FDMT Rankings

FDMT Stock Data

1.35B
26.60M
2.85%
86.46%
8.97%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
EmeryVille

About FDMT

the mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim